MICHELLE RENÉ BARNETT

Board-Certified Physician Assistant with more than 35 years of clinical experience and over two decades specializing in Gastroenterology and Hepatology. Recognized national educator, faculty leader, clinical researcher, and speaker with extensive expertise in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), chronic liver disease, fibrosis assessment, and advanced practice provider education. Serves as a national faculty member, thought leader, podcast developer, and speaker bureau member for leading healthcare organizations and pharmaceutical companies. Demonstrated leadership through professional advocacy, organizational governance, clinical research participation, and provider education at regional and national levels.

Scientific professional prepared for advancing clinical research initiatives. Known for contributing to trial success through meticulous protocol compliance and effective data management. Collaborative team player focused on achieving reliable results with adaptability and precision.

• American Academy of Physician Associates (AAPA)
• Colorado Academy of Physician Associates (CAPA)
• American Association for the Study of Liver Diseases (AASLD)
• Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)

• Colorado Physician Assistant License
• License Number 00286
• Active and in Good Standing
• Drug Enforcement Administration
• Current DEA Registration
• National Commission on Certification of Physician Assistants (NCCPA)
• Certified Physician Assistant (PA-C)
• 1986 – Present
• Recertifications:
• 1993
• 1999
• 2005
• 2011
• 2017

• GHAPP Rocky Mountain Chapter
• 4/11/26 Liver disease and Pregnancy
• GHAPP PODCASTS
• F3–F4 Fibrosis: Why Early Identification Matters
• Review of advanced fibrosis recognition, risk stratification, referral pathways, and treatment implications.
• Evaluation of Elevated Liver Function Tests
• Evidence-based diagnostic approach to abnormal liver chemistries, including laboratory interpretation, fibrosis assessment, and clinical management.
• Lifestyle Modification in MASLD/MASH
• Current evidence supporting nutritional interventions, weight reduction strategies, exercise recommendations, and long-term disease management.
• What We Learned About MASH
• Review of recent clinical developments, therapeutic advances, and evolving standards of care.
• Advances in Fibrosis Assessment
• Application of FIB-4, ELF testing, transient elastography, and emerging non-invasive diagnostic technologies.
• Emerging Therapeutics in MASLD/MASH
• Overview of treatment landscape evolution and implementation of newly available therapies.

• Current Research Activities
• Sub-Investigator
• Peak Gastroenterology Associates Research Division
• Participating in ongoing clinical studies involving gastroenterology and hepatology therapeutics.
• Prior Clinical Trials
• OPTIMAL Trial — Schering
• Boceprevir
• 2012
• ICI
• Leukotriene Antagonist in Mild to Moderate Asthma
• 1991
• Pfizer
• Azithromycin in Acute Sinusitis
• Cetirizine in Chronic Urticaria
• Cetirizine in Weed-Allergic Asthmatic Patients
• Rorer
• Nasacort in Grass-Allergic Rhinitis in Children
• 1990
• Merrell Dow
• Seldane ("Skier's Nose")
• Schering
• Unidur – Asthma
• 1989
• Fisons
• Nedocromil Calcium – Allergic Rhinitis
• Nedocromil Sodium – Allergic Rhinitis and Allergic Conjunctivitis
• Afrin / Rhinitis Medicamentosa

• GHAPP MASLD Network Podcast Developer
• Developed educational content and programming designed to improve provider awareness, diagnosis, and management of chronic liver disease and metabolic liver disorders.
• Featured Podcast Topics
• F3–F4 Fibrosis: Identification and Clinical Implications
• Evaluation of Elevated Liver Function Tests
• Lifestyle Modification Strategies for MASH
• What We Learned About MASH: Year in Review
• Fibrosis Risk Stratification
• Non-Invasive Liver Disease Assessment
• Emerging Therapeutic Options in MASH
• Advanced Practice Provider Leadership in Hepatology

• Speaker Bureau Member
• Gilead Sciences
• Madrigal Pharmaceuticals
• AbbVie
• Advisory Board Member
• Salix Pharmaceuticals
• Mirum Pharmaceutics
• Novo Nordisk

• President
• Colorado Academy of Physician Associates (CAPA)
• Provided leadership for statewide professional advocacy, educational initiatives, legislative engagement, and advancement of the physician assistant profession.
• House of Delegates Representative
• Represented Colorado physician assistants within the AAPA House of Delegates for approximately ten years, contributing to national policy development and professional governance.
• Faculty Leader
• Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
• Provides educational leadership, faculty development, curriculum planning, and mentorship for advanced practice providers specializing in gastroenterology and hepatology.
• Western Region Thought Leader
• Serves as a strategic advisor and educator on evolving standards of care in hepatology, MASLD/MASH, fibrosis assessment, and advanced practice provider integration.

• Silvers WS, Morrison MR, Wiener MD, et al. Asthma Ski Day: Cold Air Sports Safe with Peak Flow Meter Monitoring. Abstract. Annals of Allergy. 1993;70:75.
• Silvers WS, Morrison MR, LeDoux RS, et al. Aerobiology of the Colorado Rockies: Pollen Pattern Comparison of Denver and Vail. Annals of Allergy. 1992;69(5):421–426.
• Silvers WS, Morrison MR, Buckley JM, et al. Champ Camp: The Colorado Children's Asthma Camp Experience. Journal of Asthma. 1992;29(2):121–135.
• Silvers WS, Morrison MR, Wiener MD. The Skier's Nose: Evaluation of Terfenadine in Cold-Induced Rhinorrhea. Abstract. Annals of Allergy. 1992;68:87.
• Silvers WS, Morrison MR, Benninger MS. Exercise-Induced Rhinitis: A Population Survey. Abstract. Journal of Allergy and Clinical Immunology. 1991;89(1):305.